{
  "url": "https://openlegislation.uk/national-health-service-general-medical-services-contracts-prescription-of-drugs-etc-amendment-regulations-2025/note",
  "json_url": "https://openlegislation.uk/national-health-service-general-medical-services-contracts-prescription-of-drugs-etc-amendment-regulations-2025/note.json",
  "legislation": "uksi/2025/987",
  "legislation_title": "The National Health Service (General Medical Services Contracts) (Prescription of Drugs etc.) (Amendment) Regulations 2025",
  "legislation_url": "https://openlegislation.uk/national-health-service-general-medical-services-contracts-prescription-of-drugs-etc-amendment-regulations-2025",
  "path": "note",
  "kind": "note",
  "number": null,
  "heading": "Explanatory note",
  "text": "(This note is not part of the Regulations)\nThese Regulations amend the National Health Service (General Medical Services Contracts) (Prescription of Drugs etc.) Regulations 2004 (“the principal Regulations”). The principal Regulations make provision in respect of the drugs, medicines and other substances that may be ordered for patients in the provision of services under a general medical services contract within the meaning of section 84 of the National Health Service Act 2006.\nRegulation 2 makes amendments to the table in Schedule 2 to the principal Regulations (drugs, medicines and other substances that may be ordered only in certain circumstances) which restricts the circumstances in which certain drugs, medicines and other substances specified in column 1 of the table may be ordered for the category of patients described in column 2 of the table for the purposes specified in column 3 of the table.\nThe entry in the table relating to certain drugs which may only be ordered for the treatment of erectile dysfunction in restricted circumstances has been amended so as to remove the generic drugs Tadalafil and Vardenafil, and include the brand names Cialis and Levitra. The effect of this amendment is that the restrictions continue to apply to these branded versions of these two erectile dysfunction drugs.\nRegulation 2 also removes the notification requirement in relation to the prescription of the influenza antiviral treatments Oseltamivir and Zanamivir, which has the effect of allowing year-round prescribing of these treatments if the other conditions in column 2 of Schedule 2 are met.",
  "extent": null,
  "status": null,
  "version": "current",
  "annotations": [],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/uksi/2025/987/note",
    "retrieved_at": "2026-10-28T21:11:58.131446+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}